Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ABVC

ABVC - ABVC Biopharma Stock Price, Fair Value and News

$2.03-0.03 (-1.46%)
Market Closed

27/100

ABVC

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

27/100

ABVC

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.65

Target 3M

$1.89

Target 6M

$1.75

ABVC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ABVC Price Action

Last 7 days

-1.0%

Last 30 days

-12.1%

Last 90 days

-28.0%

Trailing 12 Months

275.9%

ABVC RSI Chart

ABVC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ABVC Valuation

Market Cap

49.3M

Price/Earnings (Trailing)

-9.72

Price/Sales (Trailing)

37.82

EV/EBITDA

-9.23

Price/Free Cashflow

-21.74

ABVC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.65

Target 3M

$1.89

Target 6M

$1.75

ABVC Fundamentals

ABVC Revenue

Revenue (TTM)

1.3M

Rev. Growth (Yr)

104.47%

Rev. Growth (Qtr)

40.4K%

ABVC Earnings

Earnings (TTM)

-5.1M

Earnings Growth (Yr)

-215.76%

Earnings Growth (Qtr)

44.77%

ABVC Profitability

Operating Margin

99.96%

EBT Margin

-409.17%

Return on Equity

-42.11%

Return on Assets

-23.98%

Free Cashflow Yield

-4.6%

ABVC Investor Care

Shares Dilution (1Y)

87.28%

Diluted EPS (TTM)

-0.28

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025001.3M0
2024238.0K328.6K419.1K509.6K
2023117.2K127.3K137.4K147.5K
2022000107.2K
20210000
2020568.3K000
2019470.0K547.3K624.5K701.7K
20180238.3K315.6K392.8K
201771.1K161.1K00
201600073.4K
20153.0K2.3K3.4K0
201326.9K7.8K7.8K0
20120024.9K29.9K
20110000
201000434.1K0
Get all data in R, Python etc through our Historical Stock Data APIs

About ABVC Biopharma

ABVC
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
 WEBSITEabvcpharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES19

ABVC Biopharma Frequently Asked Questions

ABVC is the stock ticker symbol of ABVC Biopharma. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of ABVC Biopharma is 49.33 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ABVC's fair value in chart for subscribers.

The fair value guage provides a quick view whether ABVC is over valued or under valued. Whether ABVC Biopharma is cheap or expensive depends on the assumptions which impact ABVC Biopharma's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABVC.

As of Wed Jan 28 2026, ABVC's PE ratio (Price to Earnings) is -9.72 and Price to Sales (PS) ratio is 37.82. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABVC PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, ABVC Biopharma has provided -0.481 (multiply by 100 for percentage) rate of return.